The present invention relates to compounds of formula I: in which A.sup.1-A.sup.7 and R.sup.1 to R.sup.5 are defined herein, for use in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). The invention also relates to pharmaceutical compounds comprising such compounds, and related methods of treatment. In an aspect, the invention relates to a method of screening compounds for therapeutic potential in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). Aspects of the invention relate to novel compounds of formula I in which at least one of A.sup.1 to A.sup.3 is or at least one of A.sup.4 is CR.sup.12 or A.sup.5 is CR.sup.13 in which R.sup.12/R.sup.13 is halogen.

Provided is a polarization source having high oxygen resistance and capable of stably transitioning the spin polarization of electron to nucleus even in an environment where oxygen exists. A polarization source for dynamic nuclear polarization containing a molecule represented by the following general formula. One to six of Z.sup.1 to Z.sup.10 each represent N, and the others each independently represent C—R. R represents a hydrogen atom or a substituent. n represents an integer of 1 to 4.

The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.

The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.

The present disclosure relates to a nitrogen heterocycle fused ring-indene compound having a structure represented by the Formula (I), ##STR00001##
in which Ar.sub.1 represents a substituted or unsubstituted aromatic fused ring group containing at least one nitrogen heteroaryl; Ar.sub.2 represents a chemical group acting as an electron donor; R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C20 alkyl, substituted or unsubstituted C3-C20 cycloalkyl, substituted or unsubstituted C1-C20 alkoxy, substituted or unsubstituted C3-C20 heterocyclyl, substituted or unsubstituted C6-C40 aryl, and substituted or unsubstituted C5-C40 heteroaryl. The compounds according to the present disclosure have high glass transition temperature and thermal stability, and are easy to form a high-quality amorphous film, so that a driving voltage can be lowered, the luminous efficiency and lifetime of the device are improved.

The present disclosure relates to a nitrogen heterocycle fused ring-indene compound having a structure represented by the Formula (I), ##STR00001##
in which Ar.sub.1 represents a substituted or unsubstituted aromatic fused ring group containing at least one nitrogen heteroaryl; Ar.sub.2 represents a chemical group acting as an electron donor; R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C20 alkyl, substituted or unsubstituted C3-C20 cycloalkyl, substituted or unsubstituted C1-C20 alkoxy, substituted or unsubstituted C3-C20 heterocyclyl, substituted or unsubstituted C6-C40 aryl, and substituted or unsubstituted C5-C40 heteroaryl. The compounds according to the present disclosure have high glass transition temperature and thermal stability, and are easy to form a high-quality amorphous film, so that a driving voltage can be lowered, the luminous efficiency and lifetime of the device are improved.

An organic light emitting element produced by using a light emitting composition that contains both a first compound having a PBHT value more than 0.730 and a second compound having ES1 lower than that of the first compound and AEsT less than 0.20 eV is excellent in durability. ES1 is the lowest excited singlet energy level, AEsT is the difference between the lowest excited singlet energy level and the lowest excited triplet energy level.

The present invention relates to (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating e.g. cardiovascular, kidney, liver, lung, skin, joints, CNS, inflammatory and autoimmune diseases.

The present invention relates to (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating e.g. cardiovascular, kidney, liver, lung, skin, joints, CNS, inflammatory and autoimmune diseases.

Compounds of general Formula (I)

##STR00001##

wherein the elements A, L, R.sup.1 and R.sup.2 have a defined meaning, and their medical and non-medical use. The compounds may be used treatment of a subject in need of any one or more of anti-inflammatory, anti-oxidative, anti-ageing, or lipid metabolism modulation therapy or prophylaxis. The compounds may also be used as food or feed products, dietary supplements or cosmetic preparations.